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Background: Although we have demonstrated a link between metabolic syndrome (MetS) and increased arterial stiffness, the relationship between 
varying definitions of MetS and arterial stiffness, particularly across ethnic groups, remains unclear. Compared to Adult Treatment Panel (ATP) III 
criteria, which appear to underestimate risk of MetS in African Americans (AAs), the World Health Organization (WHO) criteria include measures 
of insulin resistance and microalbuminuria. We hypothesized that reclassification of MetS from ATP III to WHO criteria would provide improved 
assessment of the impact of MetS on vascular function.
Methods: We classified 941 subjects (mean age 48.8 ± 11 yrs, 47% AA, 55% female) enrolled in a biracial, community-based cohort to MetS 
by ATP III and WHO criteria. Subjects were either up-reclassified (no MetS by ATPIII; MetS by WHO) or down-reclassified (MetS by ATP III; no MetS 
by WHO). Participants underwent applantation tonometry (SphygmaCor) to estimate arterial stiffness by pulse wave velocity (n=614) and central 
augmentation index (n=881).
Results: 247 subjects met criteria for MetS (111 by ATP III only, 46 by WHO only, and 90 by both ATP III and WHO); 46 subjects were up-reclassified 
from -ATPIII to +WHO (32 AA, 14 white; p=0.002) and 111 subjects were down-reclassified from +ATPIII to -WHO (56 AA, 55 white; p=0.95). 
MetS by both ATP III and WHO criteria was associated with increased pulse wave velocity and central augmentation index (p<0.05). Additionally, 
up-reclassification of MetS from -ATP III to +WHO was associated with increased arterial stiffness by pulse wave velocity (p= 0.02) and central 
augmentation index (p=0.002) compared to their non-reclassified counterparts. Conversely, down-reclassification from +ATP III to -WHO was 
associated with decreased pulse wave velocity (p=0.04) compared to their non-reclassified counterparts. 
Conclusion: Reclassification of MetS from ATP III to WHO criteria is more likely to occur in African Americans and appropriately identifies 
individuals with abnormal vascular function. Whether the WHO criteria for MetS better predict cardiovascular disease risk, especially among African 
Americans, needs to be further studied.
